ES2297030T3 - Inhibidores del transportador glyt1 y usos de los mismos en el tratamiento de trastornos neurologicos y neuropsiquiatricos. - Google Patents

Inhibidores del transportador glyt1 y usos de los mismos en el tratamiento de trastornos neurologicos y neuropsiquiatricos. Download PDF

Info

Publication number
ES2297030T3
ES2297030T3 ES02788198T ES02788198T ES2297030T3 ES 2297030 T3 ES2297030 T3 ES 2297030T3 ES 02788198 T ES02788198 T ES 02788198T ES 02788198 T ES02788198 T ES 02788198T ES 2297030 T3 ES2297030 T3 ES 2297030T3
Authority
ES
Spain
Prior art keywords
hydroxypropyl
sulfonic
group
amide
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02788198T
Other languages
English (en)
Spanish (es)
Inventor
Steven GlaxoSmithKline COULTON
Michael Stewart GlaxoSmithKline HADLEY
Hugh Jonathan GlaxoSmithKline HERDON
Jian GlaxoSmithKline JIN
Graham J. GlaxoSmithKline JOINER
Roderick Alan GlaxoSmithKline PORTER
Shahzad Sharooq GlaxoSmithKline RAHMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Application granted granted Critical
Publication of ES2297030T3 publication Critical patent/ES2297030T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES02788198T 2001-12-21 2002-12-19 Inhibidores del transportador glyt1 y usos de los mismos en el tratamiento de trastornos neurologicos y neuropsiquiatricos. Expired - Lifetime ES2297030T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0130696 2001-12-21
GBGB0130696.8A GB0130696D0 (en) 2001-12-21 2001-12-21 Chemical Compounds

Publications (1)

Publication Number Publication Date
ES2297030T3 true ES2297030T3 (es) 2008-05-01

Family

ID=9928203

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02788198T Expired - Lifetime ES2297030T3 (es) 2001-12-21 2002-12-19 Inhibidores del transportador glyt1 y usos de los mismos en el tratamiento de trastornos neurologicos y neuropsiquiatricos.

Country Status (8)

Country Link
US (1) US20050267152A1 (cg-RX-API-DMAC10.html)
EP (1) EP1455777B1 (cg-RX-API-DMAC10.html)
JP (1) JP2005519048A (cg-RX-API-DMAC10.html)
AU (1) AU2002352483A1 (cg-RX-API-DMAC10.html)
DE (1) DE60223715T2 (cg-RX-API-DMAC10.html)
ES (1) ES2297030T3 (cg-RX-API-DMAC10.html)
GB (1) GB0130696D0 (cg-RX-API-DMAC10.html)
WO (1) WO2003055478A1 (cg-RX-API-DMAC10.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0314479D0 (en) * 2003-06-20 2003-07-23 Glaxo Group Ltd Compounds
GB0314478D0 (en) * 2003-06-20 2003-07-23 Glaxo Group Ltd Compounds
EA009903B1 (ru) * 2003-10-14 2008-04-28 Пфайзер Продактс Инк. Бициклические [3.1.0] производные в качестве ингибиторов переносчиков глицина
GB0326840D0 (en) * 2003-11-18 2003-12-24 Glaxo Group Ltd Compounds
GB0329362D0 (en) * 2003-12-18 2004-01-21 Glaxo Group Ltd Compounds
GB0408772D0 (en) * 2004-04-20 2004-05-26 Glaxo Group Ltd Compounds
GB0408777D0 (en) * 2004-04-20 2004-05-26 Glaxo Group Ltd Compounds
DE602005024838D1 (en) 2004-09-30 2010-12-30 Merck Sharp & Dohme Cyclopropylpiperidinglycin-transporter-inhibitor
GB0428233D0 (en) * 2004-12-23 2005-01-26 Glaxo Group Ltd Compounds
PE20061156A1 (es) * 2004-12-23 2006-12-16 Glaxo Group Ltd Derivados de benzamida como agentes inhibidores del transportador de glicina
PE20061330A1 (es) * 2004-12-23 2006-12-27 Glaxo Group Ltd Compuestos derivados de benzamida como inhibidores del transportador de glicina
GB0428232D0 (en) * 2004-12-23 2005-01-26 Glaxo Group Ltd Compounds
JP2008525398A (ja) * 2004-12-23 2008-07-17 グラクソ グループ リミテッド グリシン輸送阻害剤
WO2007014762A2 (en) * 2005-08-02 2007-02-08 Glaxo Group Limited Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
US20090062360A1 (en) 2006-03-16 2009-03-05 Steven Coulton Compounds Which Inhibit the Glycine Transporter and Uses Thereof
GB0612425D0 (en) * 2006-06-22 2006-08-02 Glaxo Group Ltd Compounds
GB0612420D0 (en) * 2006-06-22 2006-08-02 Glaxo Group Ltd Compounds
CN101784533B (zh) * 2007-08-22 2013-08-21 艾博特股份有限两合公司 4-苄基氨基喹啉、含有它们的药物组合物和它们在治疗中的用途
EP2271625B1 (en) 2008-04-01 2012-09-12 Abbott GmbH & Co. KG Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
CA2726610C (en) * 2008-06-05 2015-05-05 Asahi Kasei Pharma Corporation Sulfonamide compounds and use thereof
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
WO2011012622A1 (en) 2009-07-30 2011-02-03 Glaxo Group Limited Benzoxazinone derivatives for the treatment of glytl mediated disorders
WO2011023753A1 (en) 2009-08-27 2011-03-03 Glaxo Group Limited Benzoxazine derivatives as glycine transport inhibitors
CN101781244B (zh) * 2010-02-10 2014-04-16 中国农业大学 化合物4-溴-n-(吡啶-2-甲基)萘-1-磺酰胺的制备方法
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
MX2014001457A (es) 2011-08-05 2014-08-21 Abbvie Deutschland Derivados de aminocromano, de aminotiocromano y de amino-1,2,3,4-tetrahidroquinolina composiciones farmaceuticas que los contienen, y su uso en terapia.
WO2013072520A1 (en) 2011-11-18 2013-05-23 AbbVie Deutschland GmbH & Co. KG N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
CA2924689A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
JP2016533375A (ja) 2013-10-17 2016-10-27 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー アミノテトラリン誘導体およびアミノインダン誘導体、これらを含有する医薬組成物、および治療におけるこれらの使用
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
JP6858712B2 (ja) 2015-01-30 2021-04-14 リーバー インスティテュート フォー ブレイン ディベロップメントＬｉｅｂｅｒ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｒａｉｎ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏｍｔ阻害方法及び組成物
WO2017091818A1 (en) 2015-11-25 2017-06-01 Lieber Institute For Brain Development Comt inhibiting methods and compositions
ES3010713T3 (en) * 2018-12-18 2025-04-04 D Western Therapeutics Inst Inc Isoquinoline sulfonyl chloride acid addition salts and method of manufacture thereof
CN115989219B (zh) * 2020-06-29 2026-02-13 贝凯恩生物医疗技术有限公司 用于治疗炎症小体介导的肺部疾病的丙磺舒化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0076072B1 (en) * 1981-09-24 1987-05-13 BEECHAM - WUELFING GmbH & Co. KG Sulphonamides
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
WO1999023072A1 (en) * 1997-10-31 1999-05-14 Suntory Limited Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same
AU2030999A (en) * 1998-01-09 1999-07-26 Allelix Neuroscience, Inc. Glycine transport inhibitors

Also Published As

Publication number Publication date
EP1455777B1 (en) 2007-11-21
WO2003055478A1 (en) 2003-07-10
US20050267152A1 (en) 2005-12-01
GB0130696D0 (en) 2002-02-06
DE60223715D1 (de) 2008-01-03
JP2005519048A (ja) 2005-06-30
AU2002352483A1 (en) 2003-07-15
EP1455777A1 (en) 2004-09-15
DE60223715T2 (de) 2008-10-30

Similar Documents

Publication Publication Date Title
JP2005519048A (ja) ＧｌｙＴ１トランスポーター阻害剤ならびに神経病学および神経精神病学的障害の治療におけるその使用
ES2469824T3 (es) Espiropiperidinas para su uso como inhibidores de la triptasa
ES2684776T3 (es) Ftalazinonas e isoquinolinonas como inhibidores de ROCK
ES2838573T3 (es) Derivados de benzamida ligados como inhibidores potentes de ROCK
ES2815681T3 (es) Ureas cíclicas como inhibidores de ROCK
KR20240062147A (ko) P53의 돌연변이체를 표적으로 하는 화합물
ES2338139T3 (es) Fenil-metanonas bi- y triciclicas sustituidas como inhibidores del transportador de la glicina i (glyt-1) para el tratamiento de la enfermedad de alzheimer.
US7030118B2 (en) Pyrrolotriazinone compounds and their use to treat diseases
CN105102448B (zh) 作为rock1和rock2抑制剂的苯基吡唑衍生物
US20100120740A1 (en) Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
ES2595240T3 (es) Derivados de tetrahidroquinazolinona como inhibidores de PARP
NO328053B1 (no) Kondenserte pyridazinderivatforbindelser og legemidler inneholdene forbindelsene som den aktive bestanddel
EP3016950A1 (en) Tricyclic pyrido-carboxamide derivatives as rock inhibitors
EP3328868A1 (en) Cyclic diarylboron derivatives as nlrp3 inflammasome inhibitors
US20110034434A1 (en) Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
JP6112316B2 (ja) テトラアザ−シクロペンタ［ａ］インデニル及びポジティブアロステリックモジュレーターとしてのそれらの使用
WO2004113301A1 (en) Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
IL300048A (en) Heterocyclic compounds with three rings, their preparation and use
US20080200454A1 (en) Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s
ES2324232T3 (es) Derivados de fenil-piperazina-metanona.
WO2004112787A1 (en) Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
ES2603420T3 (es) Derivados de 3,4-dihidropirrolo[1,2-a]pirazina-2,8(1H)-dicarboxamida, su preparación y uso terapéutico de los mismos
ES2324173T3 (es) Amidas del acido pirrolopiridin-2-carboxilico.
ES2333918T3 (es) Derivados de pirrolidina que tiene la actividad en el transportador glyt1.
ES2277237T3 (es) Compuestos de triazol utiles en terapia.